arcellx.com (ACLX) - Company Sales Volume

Risks for Arcellx (ACLX) are linked to potential clinical trial failures and the need for continuous financing. Flawless air corridors ensure a strict temperature regime during the transport of biomaterials. Arcellx is implementing next-generation CAR-T therapy for oncology centers, optimizing treatment costs. This chart of the company's aggregate realization demonstrates current trends, where 0.02 describes the current status of the metric.

Arcellx Therapeutics (ACLX): Company Revenue from 04/28/2023 to 05/09/2026

Comprehensive metric breakdowns and analytics for Arcellx, Inc. (ACLX)

- market price and analyst price targets:

Market Price Arcellx Therapeutics|ACLX - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Arcellx, Inc.|ACLX - Enterprise Value

- issuer book value statistics:

Book Value per Share Arcellx|ACLX - Company Book Value|Market Value to Book Value arcellx.com|ACLX - Company Total Assets

- debt and solvency information:

- net income and valuation ratios data:

ACLX - Net Profit|Projected Future Earnings Arcellx|ACLX - P/E Multiple|Projected Price to Earnings arcellx.com|ACLX - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcellx, Inc.|ACLX - Operating profit before deduction of amortization|Earnings per share for the last 12 months Arcellx|ACLX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months arcellx.com|ACLX - Earnings growth in current year|Earnings growth forecast for next year Arcellx

- sales volume and revenue indicators:

ACLX - Company Revenue|Company Revenue Forecast Arcellx Therapeutics|ACLX - P/S Multiple|Forward Price-to-Revenue Multiple Arcellx, Inc.

Comprehensive company analysis:Arcellx Therapeutics

Daily revenue offsets market volatility, capturing actual cash flow and the real scale of the business to assess the asset's fundamental stability. By analyzing the sales chronology of Arcellx (ACLX), an investor can track the monetization of Arcellx's successes in CAR-T therapy and the impact of the partnership with Kite Pharma on commercial expansion within the myeloma treatment segment.

Analysis of competing companies